(Reuters) — Trulieve Cannabis Corp (OTC) Corp announced a 24% jump in core profit for the fourth quarter. The increase was due to strong pot demand and related products.

This comes as the industry has attracted renewed investor attention with the U.S. House of Representatives voting on a bill to decriminalize cannabis this week.

Trulieve is a company that operates in 11 US states (Arizona, Florida and Pennsylvania). It said its fourth quarter revenues rose 81%, to $305.3million. The increase was due to Harvest Health’s $2.1 billion purchase of Trulieve.

Company stated that it expected full-year 2022 revenues to reach $1.3 billion to $1.4 trillion and adjusted core earnings to hover between $450 million and $500 million.

According to BDSA industry research firm, U.S. cannabis sales grew during the pandemic-led lockdowns and are expected to rise to $46 billion in 2026 as more states such New York or New Jersey become open to legalization.

Trulieve Cannabis shares can be listed in Canada because two major U.S. stock-exchanges don’t allow plants or sellers to list their shares. Stock is currently down 21.3% over the past year.

Investors and analysts are still requesting consolidation as a way to increase profitability and make scale-savings.

Trulieve Cannabis reported a quarter-end loss of $71.5million, compared with a profit of $3million a year ago.

Company paid $73.3 million in acquisition costs and non-recurring inventory fair value step up.